The fully automated medical PCR analyzer was approved for market release；
Received China’s first TÜV SÜD molecular diagnostics IVDR certificate;
Received clinical evaluation support worth USD 9 million from FIND and the Stop TB Partnership.
Influenza A & B and Mycoplasma pneumoniae (MP) test kits were approved by NMPA
